RPRX
Royalty Pharma plc
NASDAQ · Healthcare · Biotechnology · US
$63.96
+0.13%Margins
Gross margin
89.4%
EBITDA margin
67.7%
EBIT margin
62.3%
Net margin
32.1%
FCF margin
117.4%
11.9%
Return on equity
4.1%
Return on assets
10.0%
Return on invested capital
0.13x
Asset turnover
$3.0B
Cash from operations
$1.88
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026